0001104659-20-082444.txt : 20200709 0001104659-20-082444.hdr.sgml : 20200709 20200709182022 ACCESSION NUMBER: 0001104659-20-082444 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20200709 FILED AS OF DATE: 20200709 DATE AS OF CHANGE: 20200709 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malin Life Sciences Holdings Ltd CENTRAL INDEX KEY: 0001685138 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 201021330 BUSINESS ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO, DUBLIN STATE: L2 ZIP: ---- BUSINESS PHONE: 353 1 901 5701 MAIL ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO, DUBLIN STATE: L2 ZIP: ---- REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Malin Corp plc CENTRAL INDEX KEY: 0001673063 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 201021331 BUSINESS ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO. DUBLIN STATE: L2 ZIP: ----- BUSINESS PHONE: 353 1 901 5701 MAIL ADDRESS: STREET 1: 2 HARBOUR SQUARE STREET 2: CROFTON ROAD CITY: DUN LAOGHAIRE, CO. DUBLIN STATE: L2 ZIP: ----- ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 3 1 a3.xml 3 X0206 3 2020-07-09 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001685138 Malin Life Sciences Holdings Ltd THE LENNOX BUILDING 50 RICHMOND STREET SOUTH DUBLIN L2 D02 FK02 IRELAND 0 0 1 0 0001673063 Malin Corp plc THE LENNOX BUILDING 50 RICHMOND STREET SOUTH DUBLIN L2 D02 FK02 IRELAND 0 0 1 0 Series A Convertible Preferred Stock Common Stock 7013918 D Series A-1 Convertible Preferred Stock Common Stock 1168985 D Series B Convertible Preferred Stock Common Stock 690124 D Series C Convertible Preferred Stock Common Stock 315098 D All shares of preferred stock, $0.0001 par value per share, of the Issuer, (i) are reflective of a 1-for-1.247 reverse stock split on the Issuer's common stock, $0.0001 par value per share ("Common Stock"), which became effective on July 2, 2020, (ii) have no expiration date and (iii) will automatically convert into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares. (1) Exhibit 24 - Power of Attorney (2) Exhibit 99.1 - Joint Filer Information Malin Life Sciences Holdings Ltd, By: /s/ Michael A. Goldstein, Esq., Attorney-in-Fact 2020-07-09 Malin Corporation plc, By: /s/ Michael A. Goldstein, Esq., Attorney-in-Fact 2020-07-09 EX-24 2 ex-24.htm EX-24

Exhibit 24

 

MALIN LIFE SCIENCES HOLDINGS LTD AND MALIN CORPORATION PLC (together, the “Filer”)

LIMITED POWER OF ATTORNEY

 

KNOW ALL BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints Pat Jennings, Michael Goldstein and Brian Tribuna, subject to the expiration of this Limited Power of Attorney as set forth below, and each of them signing singly, and with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

 

(1)         execute for and on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID and the Form ID Confirming Statement, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings of a Forms 3, 4, and 5 with the SEC required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for the undersigned;

 

(2)         execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act, and the rules thereunder;

 

(3)         take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), assuming, any responsibilities of the undersigned to comply with Section 16(a) of the Exchange Act, or any other law, rule or regulation whatsoever.

 

This Limited Power of Attorney shall remain in full force and effect until the earlier of (i) the time that the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, and (iii) the revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned have caused this Limited Power of Attorney to be executed as of July 8, 2020.

 

Malin Life Sciences Holdings Ltd

 

 

 

 

By:

/s/ Fiona Dunlevy

 

Name: Fiona Dunlevy

 

 

 

Malin Corporation plc

 

 

 

By:

/s/ Darragh Lyons

 

Name: Darragh Lyons

 

 

 EX-99.1 3 ex-99d1.htm EX-99.1

Exhibit 99.1

 

FORM 3 JOINT FILER INFORMATION

 

Names of Joint Filers:

Malin Life Sciences Holdings Ltd

Malin Corporation plc

 

Address of Joint Filers:

The Lennox Building

50 Richmond Street South

Dublin

D02 FK02

Ireland

 

Designated Filer:

Malin Life Sciences Holdings Ltd

 

Issuer and Ticker Symbol:

Poseida Therapeutics, Inc. [PSTX]

 

Date of Event:

July 9, 2020

 

Signatures of Joint Filers:

 

Malin Life Sciences Holdings Ltd

 

 

 

By:

/s/ Michael A. Goldstein, Esq.

 

 

Attorney-in-Fact

 

 

 

 

Malin Corporation plc

 

 

 

By:

/s/ Michael A. Goldstein, Esq.

 

 

Attorney-in-Fact